Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Joensuu H, et al. Among authors: salminen t. J Clin Oncol. 2009 Dec 1;27(34):5685-92. doi: 10.1200/JCO.2008.21.4577. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884557 Clinical Trial.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Joensuu H, et al. Among authors: salminen t. N Engl J Med. 2006 Feb 23;354(8):809-20. doi: 10.1056/NEJMoa053028. N Engl J Med. 2006. PMID: 16495393 Free article. Clinical Trial.
Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.
Salmenkylä S, Kouri M, Österlund P, Pukkala E, Luukkonen P, Hyöty M, Pääkkönen M, Mäkelä J, Mustonen H, Järvinen HJ; Finnish Rectal Cancer Trial Group. Salmenkylä S, et al. Scand J Surg. 2012;101(4):275-82. doi: 10.1177/145749691210100410. Scand J Surg. 2012. PMID: 23238504 Clinical Trial.
Claudins as prognostic factors for renal cell cancer.
Virman J, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K, Kellokumpu-Lehtinen PL. Virman J, et al. Among authors: salminen t. Anticancer Res. 2014 Aug;34(8):4181-7. Anticancer Res. 2014. PMID: 25075044
Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.
Uutela A, Nordin A, Osterlund E, Halonen P, Kallio R, Soveri LM, Salminen T, Ålgars A, Ristimäki A, Ovissi A, Lamminmäki A, Muhonen T, Kononen J, Ristamäki R, Heervä E, Stedt H, Lehtomäki K, Kytölä S, Sundström J, Mäkinen MJ, Nieminen L, Kuopio T, Keinänen M, Osterlund P, Isoniemi H; RAXO Study Group. Uutela A, et al. Among authors: salminen t. Br J Surg. 2023 Jul 17;110(8):931-935. doi: 10.1093/bjs/znac424. Br J Surg. 2023. PMID: 36511370 Free PMC article. No abstract available.
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275. JAMA. 2010. PMID: 20823433 Clinical Trial.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Kubicka S, et al. Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. Ann Oncol. 2013. PMID: 23852309 Free article. Clinical Trial.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
272 results